About Mark Pruzanski
Mark Pruzanski is a chairman of the board at Abcuro.
Form D filings also name Mark Pruzanski as a director at eGenesis.
Mark Pruzanski reports to the SEC as a director or officer of 2 public companies: Equillium (EQ) and Intercept Pharmaceuticals (ICPT).
Mark Pruzanski first appears on SEC filings in 2012.
Experience
This experience comes from Mark Pruzanski's profile and from SEC filings. For roles taken from filings, the years are when the filings name Mark Pruzanski in the role, so the role may have started earlier or lasted longer.
AT
Alentis Therapeutics Current
Chief Executive Officer
2025 – Present
IP
Inventiva Pharma Current
Chairman of the Board
2024 – Present
VB
Verdiva Bio Current
Chairman of the Board
2024 – Present
CP
Corteria Pharmaceuticals Current
Chairman of the Board
2024 – Present
Abcuro, Inc. Current
Chairman of the Board
2023 – Present · Newton, MA
Develops immunotherapies for people with autoimmune diseases and cancer.
FL
FIGURATI LLC Current
Biotechnology Executive
2023 – Present
EI
Equillium, Inc. Current
Director
2018 – Present · Public company (EQ)
BO
Biotechnology Innovation Organization Current
Board Member
2011 – Present
FF
Foundation for Defense of Democracies (FDD) Current
Board Member
2005 – Present
II
Intercept Pharmaceuticals, Inc.
President & CEO, director
Founder, Strategic Advisor and Board Member (2002 – 2023)
2002 – 2023 · Public company (ICPT)
VB
Versanis Bio
Chief Executive Officer
2021 – 2023
EB
Evelo Biosciences
Board Member
2016 – 2017
NG
National Geographic
International Council of Advisors
2014 – 2017
GI
gIcare pharma inc
Board Member
2012 – 2016
TI
Tigris Pharmaceuticals, Inc.
Founder and Board Member
2005 – 2012
AP
Apple Tree Partners
Co-Founder and Venture Partner
1999 – 2002
OP
Oak Investment Partners
Entrepreneur In Residence
1998 – 1999
Key Colleagues at Startups
The people Mark Pruzanski works with at each company, as listed on that company's latest Form D.
Abcuro, Inc. · Form D, Aug 13, 2026
JM
John Martin
Chief Executive Officer and director
Michael Dybbs
Partner, Samsara BioCapital and director
RH
Ron Hunt
Director
Ming Fang
Managing Director, Redmile Group
Sarah Boyce
Director
eGenesis, Inc. · Form D, Feb 27, 2024
SS
Sarah Schlesinger
Director
BS
Brad Smith
Director
SG
Steven Gillis
Director
RK
Rahul Kakkar
Director
AW
Albert Wiegman
Director
JS
Julie Sunderland
Director
MC
Michael Curtis
President & CEO, director
JB
Jennifer Bergheiser
Executive officer
PS
Paul Sekhri
Director
LI
Lucio Iannone
Director
KF
Kathleen Fanning
Director